These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 10501435)

  • 21. Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs.
    Pairet M; van Ryn J
    Inflamm Res; 1998 Oct; 47 Suppl 2():S93-101. PubMed ID: 9831330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Introduction. The role of COX-2-specific inhibitors in clinical practice.
    Lipsky PE
    Am J Med; 2001 Feb; 110 Suppl 3A():1S-2S. PubMed ID: 11173042
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays.
    Riendeau D; Charleson S; Cromlish W; Mancini JA; Wong E; Guay J
    Can J Physiol Pharmacol; 1997 Sep; 75(9):1088-95. PubMed ID: 9365818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of cyclooxygenase-2 in the development and treatment of oesophageal adenocarcinoma.
    Buskens CJ; Ristimäki A; Offerhaus GJ; Richel DJ; van Lanschot JJ
    Scand J Gastroenterol Suppl; 2003; (239):87-93. PubMed ID: 14743889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of cyclooxygenase (COX) enzymes by compounds from Daucus carota L. Seeds.
    Momin RA; De Witt DL; Nair MG
    Phytother Res; 2003 Sep; 17(8):976-9. PubMed ID: 13680840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors.
    Friesen RW; Brideau C; Chan CC; Charleson S; Deschênes D; Dubé D; Ethier D; Fortin R; Gauthier JY; Girard Y; Gordon R; Greig GM; Riendeau D; Savoie C; Wang Z; Wong E; Visco D; Xu LJ; Young RN
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2777-82. PubMed ID: 9873621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?
    Warner TD; Mitchell JA
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13371-3. PubMed ID: 12374850
    [No Abstract]   [Full Text] [Related]  

  • 28. Cox-2: Where are we in 2003? - The role of cyclooxygenase-2 in bone repair.
    Einhorn TA
    Arthritis Res Ther; 2003; 5(1):5-7. PubMed ID: 12716441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanism of cyclooxygenase-2 inhibition by indanone derivatives.
    Klein T; Nüsing RM
    Adv Exp Med Biol; 1997; 407():503-7. PubMed ID: 9321998
    [No Abstract]   [Full Text] [Related]  

  • 30. Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract.
    Masferrer JL; Isakson PC; Seibert K
    Gastroenterol Clin North Am; 1996 Jun; 25(2):363-72. PubMed ID: 9229578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [COX-2 expression in gastric cancers].
    Sakamoto C
    Nihon Rinsho; 2001 Apr; 59 Suppl 4():598-603. PubMed ID: 11424449
    [No Abstract]   [Full Text] [Related]  

  • 32. Aspirin and other anti-inflammatory drugs.
    Vane SJ
    Thorax; 2000 Oct; 55 Suppl 2(Suppl 2):S3-9. PubMed ID: 10992545
    [No Abstract]   [Full Text] [Related]  

  • 33. New perspectives for nonsteroidal antiinflammatory therapy.
    de Brum-Fernandes AJ
    J Rheumatol; 1997 Feb; 24(2):246-8. PubMed ID: 9034978
    [No Abstract]   [Full Text] [Related]  

  • 34. Differentiating among nonsteroidal antiinflammatory drugs by pharmacokinetic and pharmacodynamic profiles.
    Fenner H
    Semin Arthritis Rheum; 1997 Jun; 26(6 Suppl 1):28-33. PubMed ID: 9219317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of cyclooxygenase-2 (COX-2) in breast cancer, and implications of COX-2 inhibition.
    Singh-Ranger G; Mokbel K
    Eur J Surg Oncol; 2002 Nov; 28(7):729-37. PubMed ID: 12431470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The in vivo assessment of nimesulide cyclooxygenase-2 selectivity.
    Shah AA; Murray FE; Fitzgerald DJ
    Rheumatology (Oxford); 1999 May; 38 Suppl 1():19-23. PubMed ID: 10369402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemometric rationalization of the structural and physicochemical basis for selective cyclooxygenase-2 inhibition: toward more specific ligands.
    Filipponi E; Cecchetti V; Tabarrini O; Bonelli D; Fravolini A
    J Comput Aided Mol Des; 2000 Mar; 14(3):277-91. PubMed ID: 10756482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The "aspirin" of the new millennium: cyclooxygenase-2 inhibitors.
    Buttar NS; Wang KK
    Mayo Clin Proc; 2000 Oct; 75(10):1027-38. PubMed ID: 11040851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy: preclinical basis.
    Milas L
    Am J Clin Oncol; 2003 Aug; 26(4):S66-9. PubMed ID: 12902859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
    Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.